Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 4/20 | 0.59 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.59 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | CASP6 | P55212 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
| ▸ | MAPKAPK2 | P49137 | 4/20 | 0.46 |
| ▸ | KIF11 | P52732 | 1/20 | 0.46 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methane SCHEMBL28036476 | 0.98 | CYP17A1 (0.58) | CYP17A1MAP4K4PSMB8MAPTRAB9A | |
| SCHEMBL78108 | 0.95 | MAPT (0.53) | CYP17A1MAP4K4PSMB8MAPTRAB9A | |
| Hydrochloric Acid SCHEMBL28891842 | 0.93 | MAPT (0.52) | CYP17A1MAP4K4PSMB8MAPTRAB9A | |
| SCHEMBL20865536 | 0.91 | CYP17A1 (0.68) | CYP17A1MAP4K4PSMB8CD274NAMPT | |
| SCHEMBL26643063 | 0.90 | PRMT1 (0.49) | CYP17A1MAP4K4PSMB8MAPTRAB9A | |
| SCHEMBL21049533 | 0.87 | NAMPT (0.48) | CYP17A1MAP4K4PSMB8MAPTRAB9A | |
| SCHEMBL8738157 | 0.87 | CYP17A1 (0.51) | CYP17A1MAP4K4PSMB8MAPTRAB9A | |
| SCHEMBL3781738 | 0.86 | MAP4K4 (0.50) | CYP17A1MAP4K4PSMB8CD274NAMPT | |
| SCHEMBL13379490 | 0.86 | PTPN11 (0.54) | CYP17A1MAP4K4PSMB8MAPTRAB9A | |
| SCHEMBL22461364 | 0.86 | POLB (0.67) | CYP17A1MAPTRAB9ATDP1CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250325676-A1 | CAMPTOTHECIN PRODRUG AND PHARMACEUTICAL COMPOSITION THEREOF | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO LTD (CN) | 2025-10-23 | — | — | US | disclosed |
| US-12312316-B2 | Compounds and methods for the targeted degradation of androgen receptor | ARVINAS OPERATIONS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| WO-2024238598-A2 | STAT DEGRADERS AND USES THEREOF | RECLUDIX PHARMA, INC. (US) | 2024-11-21 | — | — | WO | disclosed |
| US-20240059686-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF THE ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. (US) | 2024-02-22 | — | — | US | disclosed |
| CN-117263999-A | Camptothecin prodrugs and pharmaceutical compositions thereof | 天津和美奥康医药科技有限公司 | 2023-12-22 | — | — | CN | disclosed |
| US-11427548-B2 | Compounds and methods for the targeted degradation of androgen receptor | ARVINAS OPERATIONS, INC. (US) | 2022-08-30 | — | — | US | disclosed |
| US-11352351-B2 | Compounds and methods for the targeted degradation of androgen receptor | ARVINAS OPERATIONS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-11352351-B2 | Compounds and methods for the targeted degradation of androgen receptor | ARVINAS OPERATIONS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| EP-3658548-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | Arvinas Operations, Inc. (US) | 2020-06-03 | — | — | EP | disclosed |
| CN-111212835-A | Compounds and methods for targeted degradation of androgen receptors | 阿尔维纳斯运营股份有限公司 | 2020-05-29 | — | — | CN | disclosed |
| WO-2016118666-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF THE ANDROGEN RECEPTOR | Arvinas, Inc. (US) | 2016-07-28 | — | — | WO | disclosed |
| US-20160214972-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2016-07-28 | — | — | US | disclosed |
| WO-2016118666-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF THE ANDROGEN RECEPTOR | Arvinas, Inc. (US) | 2016-07-28 | — | — | WO | disclosed |
| CN-103019030-B | Formation method, lens and the negative-type photosensitive constituent of lens | JSR CORP. (JP) | 2016-05-04 | — | — | CN | disclosed |
| US-8383094-B2 | inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV); useful in establishing or determining the binding site of other antiviral compounds, for example, by competitive inhibition; used to treat or prevent viral contamination of materials | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-02-26 | — | — | US | disclosed |
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-04-08 | — | — | US | disclosed |
| WO-2010039793-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-04-08 | — | — | WO | disclosed |
| EP-1914221-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
| US-20030134859-A1 | PPAR-gamma modulator | SANKYO COMPANY, LIMITED (JP) | 2003-07-17 | — | — | US | disclosed |
| EP-1277729-A1 | PPAR (GAMMA) MODULATORS | Sankyo Company, Limited (JP) | 2003-01-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160214972-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ESRRA, MDM2 | CYP17A1 7/4885MAP4K4 3225/4885PSMB8 109/4885 |
| US-12312316-B2 | Compounds and methods for the targeted degradation of androgen receptor | AR, MDM2, ESRRA | CYP17A1 10/4885MAP4K4 3377/4885PSMB8 108/4885 |
| US-20030134859-A1 | PPAR-gamma modulator | PPARG, PPARA, PPARD | CYP17A1 762/4885MAP4K4 732/4885PSMB8 1902/4885 |
| US-20240059686-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF THE ANDROGEN RECEPTOR | AR, VHL, MDM2 | CYP17A1 10/4885MAP4K4 3312/4885PSMB8 110/4885 |
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | NISCH, BLVRB, BBOX1 | CYP17A1 179/4885MAP4K4 3704/4885PSMB8 4282/4885 |
| US-11352351-B2 | Compounds and methods for the targeted degradation of androgen receptor | AR, ESRRA, MDM2 | CYP17A1 7/4885MAP4K4 3225/4885PSMB8 109/4885 |
| US-20250325676-A1 | CAMPTOTHECIN PRODRUG AND PHARMACEUTICAL COMPOSITION THEREOF | TOP2B, PDE10A, REV1 | CYP17A1 1192/4885MAP4K4 4388/4885PSMB8 2167/4885 |
| US-11427548-B2 | Compounds and methods for the targeted degradation of androgen receptor | AR, MDM2, ESRRA | CYP17A1 10/4885MAP4K4 3377/4885PSMB8 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.